Search
All Clinical Trials
A listing of 23131 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 23131
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Viral Load in Blood and Lymph Tissues in People Living With HIV
Recruiting
This is a study to determine the effect of the human immunodeficiency virus (HIV) on lymphoid tissues (e.g., lymph nodes) as compared to peripheral white blood cells. We have shown in previous studies that the lymph node is a major site of accumulation of HIV in the body, as well as being a site where much of the viral replication occurs which leads to the destruction of the body's immune system. To better understand the role of the lymph node in HIV infection and destruction of one s immunity,... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: HIV
Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
Recruiting
BACKGROUND
* This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our participants, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols.
* It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cancer
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Recruiting
Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mechanisms of HES is needed in order to design more effective and less toxic therapies.
This study will investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test... Read More
Gender:
ALL
Ages:
Between 1 year and 100 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Eosinophilia, Hypereosinophilic Syndrome
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
Recruiting
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.
Healthy volunteers, as well as patients with moderate to severe eczema (AD), between 2 and 40 years of age may be eligible for this study.
We also wish to enroll children and adults aged 2-40 who... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema
Clinical and Genetic Studies of Li-Fraumeni Syndrome
Recruiting
Background:
- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is a change (called a mutation ) in a gene known as TP53. However, not all people with LFS have a TP53 mutation. Researchers want to study other possible genetic causes of LFS, and factors that may incr... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/09/2025
Locations: National Cancer Institute - Shady Grove, Bethesda, Maryland +1 locations
Conditions: Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
Recruiting
Background:
- Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers.
Objectives:
- To test the safety and efficacy of the drug combination of bortezomib and clofarabine.
Eligibility:
- Adults age 18 and over with advanced cancer that has progressed after receiving standard treatment or that has no effective therapy.
Design:
* Participants will be screened... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Myelodysplastic Syndromes, Lymphomas
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Recruiting
Background:
In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to.
Objective:
To see if signs of inflammation in CSF help predict a person s response to different drugs.
Eligibility:
People ages 18 and older who:
* Are in protocol 09-I-003... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
Recruiting
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During thi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/09/2025
Locations: Banner Desert Medical Center, Mesa, Arizona +75 locations
Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
Recruiting
Background:
Turner Syndrome, galactosemia, and premature ovarian insufficiency are all conditions that may make it very hard or impossible for a person to become pregnant and have their own child. Researchers want to learn more about why this happens and if freezing Gonadal tissue allows for fertility preservation.
Objective:
To find out why people with certain conditions have can have premature ovarian insufficiency (POI or early menopause) and individuals with variations in sex characterist... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Ovarian Disfunction, Post-menarcheal Adolescents, Turner Syndrome, Galactosemia, Variations in Sex Characteristics, Differences in Sex Development
Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin
Recruiting
This protocol describes a randomized, open-label study to evaluate the safety and tolerability of single-dose intravenous (IV) oritavancin diphosphate (oritavancin) versus standard of care (SoC) antibiotics for the treatment of pediatric subjects with acute bacterial skin and skin structure infections (ABSSSIs).
This study involves two oritavancin products, ORBACTIV® and KIMYRSATM. Oritavancin is the active drug substance in both ORBACTIV and KIMYRSA. This study protocol distinguishes the diffe... Read More
Gender:
ALL
Ages:
Between 3 months and 17 years
Trial Updated:
07/09/2025
Locations: Tampa General Hospital, Tampa, Florida +28 locations
Conditions: Acute Bacterial Skin and Skin Structure Infection
ACP-204 in Adults With Alzheimer's Disease Psychosis
Recruiting
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP
* Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first.
* Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B wi... Read More
Gender:
ALL
Ages:
Between 55 years and 95 years
Trial Updated:
07/09/2025
Locations: Advanced Research Center, Inc., Anaheim, California +122 locations
Conditions: Alzheimer's Disease Psychosis
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
Recruiting
This study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/09/2025
Locations: Associated Retina Consultants, Gilbert, Arizona +42 locations
Conditions: Geographic Atrophy
1 - 12 of 23131